<SEC-DOCUMENT>0000939767-25-000074.txt : 20250513
<SEC-HEADER>0000939767-25-000074.hdr.sgml : 20250513
<ACCEPTANCE-DATETIME>20250513161001
ACCESSION NUMBER:		0000939767-25-000074
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		16
CONFORMED PERIOD OF REPORT:	20250513
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250513
DATE AS OF CHANGE:		20250513

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			EXELIXIS, INC.
		CENTRAL INDEX KEY:			0000939767
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				043257395
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0102

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-30235
		FILM NUMBER:		25940147

	BUSINESS ADDRESS:	
		STREET 1:		1851 HARBOR BAY PARKWAY
		CITY:			ALAMEDA
		STATE:			CA
		ZIP:			94502
		BUSINESS PHONE:		6508377000

	MAIL ADDRESS:	
		STREET 1:		1851 HARBOR BAY PARKWAY
		CITY:			ALAMEDA
		STATE:			CA
		ZIP:			94502

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EXELIXIS INC
		DATE OF NAME CHANGE:	20000207

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EXELIXIS PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	20000106
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>exel-20250513.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:afe5a4b8-9f29-4ee5-a450-454430305d0f,g:26d60216-afbf-47d0-b127-e6d76e60a090,d:cab2aaa7a24b4d32b1552f506104a1ff-->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xlink="http://www.w3.org/1999/xlink" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>exel-20250513</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-month-day-year" id="f-21">5/13/2025</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-22">0000939767</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" id="f-23">false</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="exel-20250513.xsd"/></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-05-13</xbrli:startDate><xbrli:endDate>2025-05-13</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="icab2aaa7a24b4d32b1552f506104a1ff_1"></div><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:16pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:16pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:200.25pt"><tr><td style="width:1.0pt"/><td style="width:108.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:88.00pt"/><td style="width:1.0pt"/></tr><tr style="height:20pt"><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:16pt;font-weight:700;line-height:100%">FORM</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:16pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">8-K</ix:nonNumeric></span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CURRENT REPORT </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO SECTION 13 OR 15(d) OF THE </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECURITIES EXCHANGE ACT OF 1934 </span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Date of Report (Date of earliest event reported): <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-2">May 13, 2025</ix:nonNumeric></span></div><div style="margin-top:9pt;text-align:center"><span><br/></span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:200.25pt"><tr><td style="width:1.0pt"/><td style="width:198.25pt"/><td style="width:1.0pt"/></tr><tr style="height:47pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"><div style="text-align:center"><img src="exel-20250513_g1.jpg" alt="Exelixis_Logo_RGB_2023.jpg" style="height:47px;margin-bottom:5pt;vertical-align:text-bottom;width:177px" id="i-1"/></div></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:16pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-3">EXELIXIS, INC.</ix:nonNumeric></span></div></td></tr><tr style="height:12pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Exact name of registrant as specified in its charter)</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.619%"><tr><td style="width:1.0%"/><td style="width:38.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.174%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:39.145%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-4">Delaware</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">000-30235</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-6">04-3257395</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(State or Other Jurisdiction of Incorporation)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Commission File Number)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(IRS Employer Identification No.)</span></div></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-7">1851 Harbor Bay Parkway</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-8">Alameda</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-9">California</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-10">94502</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Address of principal executive offices) (Zip Code)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-11">650</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-12">837-7000</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Registrant&#8217;s telephone number, including area code) </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): </span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="f-13">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="f-14">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="f-15">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="f-16">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </span></div><div><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section&#160;12(b) of the Act:</span></div><div style="margin-top:3pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.553%"><tr><td style="width:1.0%"/><td style="width:39.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.780%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:38.363%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 5.5pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Trading Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:2px 5.5pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-17">Common Stock $0.001 Par Value per Share</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-18">EXEL</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-19">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter). Emerging growth company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="f-20">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="icab2aaa7a24b4d32b1552f506104a1ff_7"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.02.  Results of Operations and Financial Condition.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May&#160;13, 2025, Exelixis, Inc. (Exelixis) issued a press release announcing its financial results for the quarter ended April&#160;4, 2025, and providing a corporate update. A copy of such press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information in this report, including the exhibit hereto, shall not be deemed &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this report and in the accompanying exhibit shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by Exelixis, whether made before or after the date hereof, regardless of any general incorporation language in such filing. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9.01.  Financial Statements and Exhibits.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(d) &#160;&#160;&#160;&#160;Exhibits.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.553%"><tr><td style="width:1.0%"/><td style="width:8.914%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.995%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:33.429%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.995%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:51.967%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit Number</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit Description</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exel20250331exhibit991.htm">Press Release issued May 13, 2025</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="icab2aaa7a24b4d32b1552f506104a1ff_10"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </span></div><div style="margin-top:5pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.428%"><tr><td style="width:1.0%"/><td style="width:26.608%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:54.526%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">E</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">XELIXIS, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">NC.</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 13, 2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Jeffrey J. Hessekiel</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Jeffrey J. Hessekiel</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President and General Counsel <br/></span></td></tr></table></div><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exel20250331exhibit991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="ia43dbc3c1fd4451dbfb5b93ef7c2b03a_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit 99.1</font></div></div><div style="margin-top:9pt"><img alt="imagea.jpg" src="imagea.jpg" style="height:47px;margin-bottom:5pt;vertical-align:text-bottom;width:175px"></div><div style="margin-top:9pt;text-align:justify"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Contacts&#58;</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Chris Senner</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Chief Financial Officer</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Exelixis, Inc.</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">650-837-7240</font></div><div style="text-align:right"><font style="color:#006ba6;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">csenner&#64;exelixis.com</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Susan Hubbard</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%">EVP, Public Affairs &#38; Investor Relations</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Exelixis, Inc.</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">650-837-8194</font></div><div style="text-align:right"><font style="color:#006ba6;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%;text-decoration:underline">shubbard&#64;exelixis.com</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exelixis Announces First Quarter 2025 Financial Results and Provides Corporate Update</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">- Total Revenues of $555.4 million, Cabozantinib Franchise U.S. Net Product Revenues of $513.3 million -</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">- GAAP Diluted EPS of $0.55, Non-GAAP Diluted EPS of $0.62 -</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">- Increasing 2025 Full Year Net Product Revenues and Total Revenues Guidance by $100 million -</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">- Conference Call and Webcast Today at 5&#58;00 PM Eastern Time -</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">ALAMEDA, Calif. &#8211; May&#160;13, 2025 - Exelixis, Inc. (Nasdaq&#58; EXEL) today reported financial results for the first quarter of 2025, provided an update on progress toward achieving key corporate objectives, and outlined its commercial, clinical and pipeline development milestones.</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;Exelixis delivered outstanding financial performance in the first quarter of 2025, driven by accelerating growth in CABOMETYX&#174; demand, new patient starts and revenues,&#8221; said Michael M. Morrissey, Ph.D., President and Chief Executive Officer, Exelixis. &#8220;Based on the strong first quarter dynamics of CABOMETYX, we&#8217;re increasing our 2025 full year financial guidance for net product revenues and total revenues by $100 million. The Exelixis commercial team rapidly mobilized for the launch of CABOMETYX in advanced neuroendocrine tumors (NET) within hours of receiving U.S. regulatory approval in late March. We are very pleased with the initial reception and plan to provide further updates to our 2025 financial guidance as we build momentum on the NET launch and gain further clarity on additional revenue opportunities for 2025.&#8221;</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Dr. Morrissey continued&#58; &#8220;As we work toward our goal of becoming a multi-franchise oncology company, we look forward to important potential milestones for zanzalintinib in the second half of 2025, based on anticipated event rates. These include pivotal trial readouts from STELLAR-303 in colorectal cancer and STELLAR-304 in non-clear cell renal cell carcinoma, as well as data to drive a decision to move into the phase 3 portion of the STELLAR-305 trial in head and neck cancer. We also look forward to the initiation of the STELLAR-311 pivotal study in neuroendocrine tumors in the first half of the year, and Merck&#8217;s anticipated initiation of two pivotal studies evaluating zanzalintinib and belzutifan in renal cell carcinoma. Furthermore, we continue to provide insights on our earlier-stage pipeline, with preclinical data presented on multiple programs at the AACR Annual Meeting in April. I&#8217;m proud of the entire Exelixis team for our progress so far in 2025 and look forward to sharing additional updates throughout the year.&#8221;</font></div><div style="margin-top:9pt;text-align:justify"><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;- more - </font></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-top:9pt;text-align:justify"><font><br></font></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.899%"><tr><td style="width:1.0%"></td><td style="width:57.957%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exelixis First Quarter 2025 Financial Results</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Page 2 of 8</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">May&#160;13, 2025</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:115%;text-decoration:underline">First Quarter 2025 Financial Results</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Total revenues </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">for the quarter ended March&#160;31, 2025</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">were $555.4&#160;million, as compared to $425.2&#160;million for the comparable period in 2024. </font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total revenues for the quarter ended March&#160;31, 2025 included net product revenues of $513.3 million, as compared to $378.5&#160;million for the comparable period in 2024. The increase in net product revenues was primarily due to an increase in sales volume and an increase in average net selling price.</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Collaboration revenues, composed of license revenues and collaboration services revenues, were $42.2&#160;million for the quarter ended March&#160;31, 2025, as compared to $46.7&#160;million for the comparable period in 2024. The decrease in collaboration revenues was primarily related to lower royalty revenues for the sales of cabozantinib outside of the U.S. generated by Exelixis&#8217; collaboration partners, Ipsen Pharma SAS (Ipsen) and Takeda Pharmaceutical Company Limited, and lower development cost reimbursements earned. </font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Research and development expenses</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> for the quarter ended March&#160;31, 2025 were $212.2&#160;million, as compared to $227.7&#160;million for the comparable period in 2024. The decrease in research and development expenses was primarily related to decreases in license and other collaboration costs and clinical trial costs, partially offset by increases in stock-based compensation and personnel expenses.</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Selling, general and administrative expenses</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> for the quarter ended March&#160;31, 2025 were $137.2&#160;million, as compared to $114.0 million for the comparable period in 2024. The increase in selling, general and administrative expenses was primarily related to increases in personnel expenses, corporate giving, and marketing expenses.</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Provision for income taxes </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">for the quarter ended March&#160;31, 2025 was $46.1 million, as compared to $12.0&#160;million for the comparable period in 2024.</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">GAAP net income </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">for the quarter ended March&#160;31, 2025 was $159.6&#160;million, or $0.57 per share, basic and $0.55 per share, diluted, as compared to GAAP net income of $37.3&#160;million, or $0.12 per share, basic and diluted, for the comparable period in 2024. GAAP net income per share for the quarter ended March&#160;31, 2025 was favorably impacted by lower weighted-average common shares outstanding for the quarter ended March&#160;31, 2025, as compared to the comparable period in 2024, as a result of the stock repurchase programs.</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Non-GAAP net income </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">for the quarter ended March&#160;31, 2025 was $179.6&#160;million, or $0.64&#160;per share, basic and $0.62 per share, diluted, as compared to non-GAAP net income of $52.0&#160;million, or $0.17&#160;per share, basic and diluted, for the comparable period in 2024. </font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Non-GAAP Financial Measures</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">To supplement Exelixis&#8217; financial results presented in accordance with U.S. Generally Accepted Accounting Principles (GAAP), Exelixis presents non-GAAP net income (and the related per share measures), which excludes from GAAP net income (and the related per share measures) stock-based compensation, adjusted for the related income tax effect for all periods presented.</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Exelixis believes that the presentation of these non-GAAP financial measures provides useful supplementary information to, and facilitates additional analysis by, investors. In particular, Exelixis believes that these non-GAAP financial measures, when considered together with its financial information prepared in accordance with GAAP, can enhance investors&#8217; and analysts&#8217; ability to meaningfully compare Exelixis&#8217; results from period to period, and to identify operating trends in Exelixis&#8217; business. Exelixis has excluded stock-based compensation, adjusted for the related income tax effect, because it is a non-cash item that may vary significantly from period to period as a result of changes not directly or immediately related to the operational performance for the periods presented. Exelixis also regularly uses these non-GAAP financial measures internally to understand, manage and evaluate its business and to make operating decisions.</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;- more - </font></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-top:9pt;text-align:justify"><font><br></font></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.899%"><tr><td style="width:1.0%"></td><td style="width:57.957%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exelixis First Quarter 2025 Financial Results</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Page 3 of 8</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">May&#160;13, 2025</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">These non-GAAP financial measures are in addition to, not a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP. Exelixis encourages investors to carefully consider its results under GAAP, as well as its supplemental non-GAAP financial information and the reconciliation between these presentations, to more fully understand Exelixis&#8217; business. Reconciliations between GAAP and non-GAAP results are presented in the tables of this release.</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">2025 Financial Guidance</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Exelixis is providing the following updated financial guidance for fiscal year 2025&#58; </font></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.560%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.069%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.071%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Current Guidance</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(provided on May 13, 2025)</font></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Previous Guidance</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(provided on January 12, 2025)</font></div></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total revenues</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline"> </font></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$2.25 billion - $2.35 billion</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$2.15 billion - $2.25 billion</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Net product revenues </font></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$2.05 billion - $2.15 billion</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">(1)</font></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$1.95 billion - $2.05 billion</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">(1)</font></div></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Cost of goods sold</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4% - 5% of net product revenues</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4% - 5% of net product revenues</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Research and development expenses </font></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$925 million - $975 million</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">(2)</font></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$925 million - $975 million</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">(4)</font></div></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Selling, general and administrative expenses </font></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$475 million - $525 million</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">(3)</font></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$475 million - $525 million</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">(5)</font></div></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Effective tax rate</font></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">21% - 23%</font></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">21% - 23%</font></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">____________________</font></div><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1) </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Exelixis&#8217; 2025 net product revenues guidance range includes the impact of a U.S. wholesale acquisition cost increase of 2.8% for  CABOMETYX effective Jan. 1, 2025.</font></div><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2) </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Includes $50.0 million of non-cash stock-based compensation.</font></div><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3) </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Includes $80.0 million of non-cash stock-based compensation.</font></div><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(4) </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Includes $40.0 million of non-cash stock-based compensation.</font></div><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(5) </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Includes $60.0 million of non-cash stock-based compensation.</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Cabozantinib and Pipeline Highlights</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Cabozantinib Franchise Net Product Revenues and Royalties.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> Net product revenues generated by the cabozantinib franchise in the U.S. were $513.3 million during the first quarter of 2025, with net product revenues of $510.9 million from CABOMETYX (cabozantinib) and $2.4 million from COMETRIQ&#174; (cabozantinib). Based upon cabozantinib-related net product revenues generated by Exelixis&#8217; collaboration partners during the quarter ended March 31, 2025, Exelixis earned $36.7 million in royalty revenues.</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Received U.S. Food and Drug Administration (FDA) Approval of CABOMETYX for Patients with Previously Treated Advanced NET. </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In March, Exelixis announced that the U.S. FDA approved CABOMETYX for the treatment of 1) adult and pediatric patients 12 years of age and older with previously treated, unresectable, locally advanced or metastatic, well-differentiated pancreatic NET (pNET)&#59; and 2) adult and pediatric patients 12 years of age and older with previously treated, unresectable, locally advanced or metastatic, well-differentiated extra-pancreatic NET (epNET). These latest FDA approvals &#8212; adding to five previous approvals for CABOMETYX &#8212; are based on results from CABINET, a phase 3 pivotal trial evaluating CABOMETYX compared with placebo in two cohorts of patients with previously treated NET&#58; advanced pNET and advanced epNET. CABOMETYX is now the first and only systemic treatment that is FDA approved for previously treated NET regardless of primary tumor site, grade, somatostatin receptor expression and functional status. NET are heterogeneous tumors that arise from the neuroendocrine cells of the digestive tract and other organs, such as the lung and pancreas.</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Announced Final Five-Year Follow-up Results from CheckMate -9ER Trial Evaluating CABOMETYX in Combination with Nivolumab (Opdivo&#174;) in Patients with Advanced Kidney Cancer at the American Society of Clinical Oncology 2025 Genitourinary Cancers Symposium</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(ASCO GU 2025). </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In February, final results from the phase 3 CheckMate -9ER pivotal trial evaluating CABOMETYX in combination with nivolumab versus sunitinib for patients with previously untreated advanced renal cell carcinoma (RCC) were presented at ASCO GU 2025. After more than five years of follow-up, the findings demonstrated that efficacy benefits with CABOMETYX in </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;- more - </font></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-top:9pt;text-align:justify"><font><br></font></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.899%"><tr><td style="width:1.0%"></td><td style="width:57.957%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exelixis First Quarter 2025 Financial Results</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Page 4 of 8</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">May&#160;13, 2025</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">combination with nivolumab were sustained long term. Safety and tolerability with long-term follow-up were manageable and consistent with previous analyses. No new safety signals were reported.</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Detailed Results from Subgroup Analysis of Phase 3 CABINET Pivotal Study Evaluating Cabozantinib in Advanced Gastrointestinal (GI) NET Presented at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI 2025). </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In January, results from a subgroup analysis of the CABINET study of patients with epNET arising in the GI tract were featured in a poster session at ASCO GI 2025. The analysis showed cabozantinib was associated with an improvement in progression-free survival (PFS) compared with placebo in patients with advanced GI NET, which was a subgroup of the epNET cohort. Earlier in January, the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology for Neuroendocrine and Adrenal Tumors were updated to include cabozantinib as category 1 preferred regimen for the majority of well-differentiated advanced NET following specific treatments, and as a category 2A preferred regimen for other forms of advanced NET, depending on tumor grade and different requirements for prior therapy.</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Encouraging Results from Phase 1b&#47;2 STELLAR-001 Trial Evaluating Zanzalintinib Alone or in Combination with Atezolizumab (Tecentriq&#174;) in Metastatic Colorectal Cancer (CRC) Presented at ASCO GI 2025.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> In January, results from a randomized expansion cohort of the phase 1b&#47;2 STELLAR-001 trial evaluating zanzalintinib versus the combination of zanzalintinib and atezolizumab in patients with previously treated metastatic CRC were presented during a poster session at ASCO GI 2025. Results from the study demonstrated that all efficacy parameters, including objective response rate, PFS and overall survival favored the combination of zanzalintinib plus atezolizumab over zanzalintinib monotherapy in the overall population, as well as in a subgroup of patients without liver metastases. These data provide insights into the contribution of components and support zanzalintinib&#8217;s ongoing pivotal development in metastatic CRC.</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Presentation of Preclinical Data from Four Pipeline Programs in Advanced Cancers at the American Association for Cancer Research Annual Meeting (AACR 2025). </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In April, Exelixis presented preclinical data from four pipeline molecules at AACR 2025. Presentations included data for XL309 and XL495, small molecules that have demonstrated synthetic lethality in the context of certain genetic anomalies found in varying frequencies across a broad array of tumor types. The XL309 findings demonstrated activity of XL309 as monotherapy or in combination with PARP or topoisomerase inhibitors. Data analysis from the XL495 program demonstrated the potential for anti-tumor activity both as a monotherapy and in combination with DNA-damaging agents. However, based on early clinical data generated for XL495, Exelixis has discontinued further development of this program. Preclinical data were also presented for the PD-L1 + NKG2A-targeting bispecific antibody XB628 and for the tissue factor-targeting antibody-drug conjugate XB371. Data analysis from the XB628 program demonstrated the molecule&#8217;s tumor cell killing activity both </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">in vitro</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> and </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">in vivo</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, supporting advancement of this molecule into clinical development. Earlier in March, the U.S. FDA cleared Exelixis&#8217; Investigational New Drug (IND) application for XB628, and the company initiated the phase 1 study in April. Findings from XB371 non-clinical experiments demonstrated potent</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">anti-tumor activity </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">in vivo</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> across a range of human tumor xenograft models including colorectal, lung, and pancreatic cancers, supporting the molecule&#8217;s advancement into phase 1 clinical development. Exelixis is on track to submit an IND application for XB371 to the FDA in 2025. </font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Cabozantinib and Zanzalintinib Data Presentations at the 2025 American Society of Clinical Oncology Annual Meeting (ASCO 2025). </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Cabozantinib and zanzalintinib will be the subject of 17 presentations at ASCO 2025, which is being held from May 30 through June 3 in Chicago. Notably, presentations will include health-related quality of life findings from the phase 3 CABINET pivotal trial for cabozantinib, as well as results from two dose-escalation cohorts in advanced solid tumors and a clear cell RCC expansion cohort of the phase 1b&#47;2 STELLAR-002 trial evaluating zanzalintinib in combination with immune checkpoint inhibitors in advanced solid tumors.</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;- more - </font></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-top:9pt;text-align:justify"><font><br></font></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.899%"><tr><td style="width:1.0%"></td><td style="width:57.957%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exelixis First Quarter 2025 Financial Results</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Page 5 of 8</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">May&#160;13, 2025</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Corporate Highlights</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Stock Repurchase Program. </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">In August 2024, Exelixis&#8217; Board of Directors authorized a stock repurchase program to acquire up to $500 million of the company&#8217;s common stock before December 31, 2025. In February 2025, the Board of Directors authorized the repurchase of up to an additional $500 million of the company&#8217;s common stock before December 31, 2025. Under these programs, as of March 31, 2025, Exelixis has repurchased $494.5 million of the company&#8217;s common stock, at an average price of $34.87 per share. Since the approval of the first stock repurchase program in March 2023, the weighted-average diluted common shares outstanding has decreased from 326.3 million shares to 288.2 million shares as of March 31, 2025. Stock repurchases under these programs may be made from time to time through a variety of methods, which may include open market purchases, in block trades, accelerated share repurchase transactions, exchange transactions, or any combination of such methods. The timing and amount of any stock repurchases under the stock repurchase programs will be based on a variety of factors, including ongoing assessments of the capital needs of the business, alternative investment opportunities, the market price of our common stock and general market conditions.</font></div><div style="margin-bottom:3pt;margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Basis of Presentation</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Exelixis has adopted a 52- or 53-week fiscal year that generally ends on the Friday closest to December&#160;31. For convenience, references in this press release as of and for the fiscal periods ended April&#160;4, 2025 and March 29, 2024, are indicated as being as of and for the periods ended</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">March&#160;31, 2025 and March&#160;31, 2024</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">.</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Conference Call and Webcast</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Exelixis management will discuss the company&#8217;s financial results for the first quarter 2025 and provide a general business update during a conference call beginning at 5&#58;00&#160;p.m. ET &#47; 2&#58;00&#160;p.m. PT today, Tuesday, May&#160;13, 2025.</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">To access the conference call, please register using this </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">link</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Upon registration, a dial-in number and unique PIN will be provided to join the call. To access the live webcast link, log onto </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">www.exelixis.com</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> and proceed to the Event Calendar page under the Investors &#38; News heading. A webcast replay of the conference call will also be archived on </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">www.exelixis.com</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> for one year.</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">About Exelixis</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Exelixis is a globally ambitious oncology company innovating next-generation medicines and regimens at the forefront of cancer care. Powered by drug discovery and development excellence, we are rapidly evolving our product portfolio to target an expanding range of tumor types and indications with our clinically differentiated pipeline of small molecules, antibody-drug conjugates and other biotherapeutics. This comprehensive approach harnesses decades of robust investment in our science and partnerships to advance our investigational programs and extend the impact of our flagship commercial product, CABOMETYX&#174; (cabozantinib). Exelixis is driven by a bold scientific pursuit to create transformational treatments that give more patients hope for the future. For information about the company and its mission to help cancer patients recover stronger and live longer, visit </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">www.exelixis.com</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, follow </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">&#64;ExelixisInc</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> on X (Twitter), like </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Exelixis, Inc.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> on Facebook and follow Exelixis on LinkedIn.</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Forward-Looking Statements</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">This press release contains forward-looking statements, including, without limitation, statements related to&#58; Exelixis&#8217; updated 2025 financial guidance and any plans to provide further updates&#59; Exelixis&#8217; goal of becoming a multi-franchise oncology company&#59; anticipated zanzalintinib pivotal data milestones with respect to the STELLAR-303, STELLAR-304 and STELLAR-305 trials&#59; Exelixis&#8217; anticipated timing to initiate the STELLAR-311 pivotal study in neuroendocrine tumors in the first half of 2025&#59; Exelixis&#8217; expectations with respect to its clinical development collaboration with Merck&#59; Exelixis&#8217; plans to submit an IND application for XB371 to the FDA in 2025&#59; Exelixis&#8217; plans to present data at ASCO 2025&#59; and Exelixis&#8217; scientific pursuit to create transformational treatments that give more patients hope for the future. Any statements that refer to expectations, projections </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;- more - </font></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-top:9pt;text-align:justify"><font><br></font></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.899%"><tr><td style="width:1.0%"></td><td style="width:57.957%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exelixis First Quarter 2025 Financial Results</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Page 6 of 8</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">May&#160;13, 2025</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">or other characterizations of future events or circumstances are forward-looking statements and are based upon Exelixis&#8217; current plans, assumptions, beliefs, expectations, estimates and projections. Forward-looking statements involve risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in the forward-looking statements as a result of these risks and uncertainties, which include, without limitation&#58; the degree of market acceptance of CABOMETYX and other Exelixis products in the indications for which they are approved and in the territories where they are approved, and Exelixis&#8217; and its partners&#8217; ability to obtain or maintain coverage and reimbursement for these products&#59; the effectiveness of CABOMETYX and other Exelixis products in comparison to competing products&#59; the level of costs associated with Exelixis&#8217; commercialization, research and development, in-licensing or acquisition of product candidates, and other activities&#59; Exelixis&#8217; ability to maintain and scale adequate sales, marketing, market access and product distribution capabilities for its products or to enter into and maintain agreements with third parties to do so&#59; the availability of data at the referenced times&#59; the potential failure of cabozantinib, zanzalintinib and other Exelixis product candidates, both alone and in combination with other therapies, to demonstrate safety and&#47;or efficacy in clinical testing&#59; uncertainties inherent in the drug discovery and product development process&#59; Exelixis&#8217; dependence on its relationships with its collaboration partners, including their pursuit of regulatory approvals for partnered compounds in new indications, their adherence to their obligations under relevant collaboration agreements and the level of their investment in the resources necessary to complete clinical trials or successfully commercialize partnered compounds in the territories where they are approved&#59; complexities and the unpredictability of the regulatory review and approval processes in the U.S. and elsewhere&#59; Exelixis&#8217; continuing compliance with applicable legal and regulatory requirements&#59; unexpected concerns that may arise as a result of the occurrence of adverse safety events or additional data analyses of clinical trials evaluating cabozantinib, zanzalintinib and other Exelixis product candidates&#59; Exelixis&#8217; dependence on third-party vendors for the development, manufacture and supply of its products and product candidates&#59; Exelixis&#8217; ability to protect its intellectual property rights&#59; market competition, including the potential for competitors to obtain approval for generic versions of Exelixis&#8217; marketed products&#59; changes in economic and business conditions, including as a result of changing trade policies and tariffs and the related uncertainty thereof&#59; and other factors detailed from time to time under the caption &#8220;Risk Factors&#8221; in Exelixis&#8217; most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q, and in Exelixis&#8217; other future filings with the Securities and Exchange Commission. All forward-looking statements in this press release are based on information available to Exelixis as of the date of this press release, and Exelixis undertakes no obligation to update or revise any forward-looking statements contained herein, except as required by law.</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Exelixis, the Exelixis logo, CABOMETYX and COMETRIQ are registered trademarks of Exelixis, Inc.</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">OPDIVO&#174; is a registered trademark of Bristol Myers Squibb.</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">TECENTRIQ (atezolizumab) is a registered trademark of Genentech, a member of the Roche Group.</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">-see attached financial tables-</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;- more - </font></td></tr></table></div></div></div><div id="ia43dbc3c1fd4451dbfb5b93ef7c2b03a_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-top:9pt;text-align:justify"><font><br></font></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.899%"><tr><td style="width:1.0%"></td><td style="width:57.957%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exelixis First Quarter 2025 Financial Results</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Page 7 of 8</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">May&#160;13, 2025</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">EXELIXIS, INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF INCOME </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(in thousands, except per share amounts)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(unaudited)</font></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:66.411%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.847%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended March 31,</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2025</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Revenues&#58;</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Net product revenues</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">513,283&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">378,523&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Collaboration revenues</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">42,164&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">46,703&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total revenues</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">555,447&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">425,226&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Operating expenses&#58;</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Cost of goods sold</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">19,172&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">21,256&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Research and development</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">212,233&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">227,689&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Selling, general and administrative</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">137,183&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">113,984&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Restructuring</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">32,835&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total operating expenses</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">368,588&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">395,764&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Income from operations</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">186,859&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">29,462&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Interest income</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">19,076&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">19,894&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Other expenses, net</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(245)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(89)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Income before income taxes</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">205,690&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">49,267&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Provision for income taxes</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">46,074&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11,950&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Net income</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">159,616&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">37,317&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Net income per share&#58;</font></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.25pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Basic</font></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.57&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.12&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Diluted</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.55&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.12&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Basic</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">278,804&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">300,757&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Diluted</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">288,177&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">305,530&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font><br></font></div><div style="margin-top:9pt;text-align:justify"><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;- more - </font></td></tr></table></div></div></div><div id="ia43dbc3c1fd4451dbfb5b93ef7c2b03a_7"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-top:9pt;text-align:justify"><font><br></font></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.899%"><tr><td style="width:1.0%"></td><td style="width:57.957%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exelixis First Quarter 2025 Financial Results</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Page 8 of 8</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">May&#160;13, 2025</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">EXELIXIS, INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">RECONCILIATION OF GAAP NET INCOME TO NON-GAAP NET INCOME </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(in thousands, except per share amounts)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(unaudited)</font></div><div style="margin-top:9pt;text-align:justify"><font><br></font></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.553%"><tr><td style="width:1.0%"></td><td style="width:66.613%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.744%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.397%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.746%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended March 31,</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2025</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">GAAP net income</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">159,616&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">37,317&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Adjustments&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Stock-based compensation - research and development</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9,522&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3,892&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Stock-based compensation - selling, general and administrative</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">16,408&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15,221&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Income tax effect of the above adjustments</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(5,993)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(4,448)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Non-GAAP net income</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">179,553&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">51,982&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">GAAP net income per share&#58;</font></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Basic</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.57&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.12&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Diluted&#160;</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.55&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.12&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Non-GAAP net income per share&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Basic</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.64&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.17&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Diluted </font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.62&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.17&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Basic</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">278,804&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">300,757&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Diluted</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">288,177&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">305,530&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">____________________</font></div><div style="padding-left:7.2pt;text-indent:-7.2pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1) </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Non-cash stock-based compensation used for GAAP reporting in accordance with Accounting Standards Codification Topic 718, </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Compensation&#8212;Stock Compensation</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.</font></div><div style="padding-left:18pt;text-indent:-18pt"><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:justify"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>exel-20250513.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:afe5a4b8-9f29-4ee5-a450-454430305d0f,g:26d60216-afbf-47d0-b127-e6d76e60a090-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:exel="http://www.exelixis.com/20250513" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.exelixis.com/20250513">
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="exel-20250513_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="exel-20250513_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.exelixis.com/role/CoverPage">
        <link:definition>0000001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>exel-20250513_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:afe5a4b8-9f29-4ee5-a450-454430305d0f,g:26d60216-afbf-47d0-b127-e6d76e60a090-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_8c40a8f8-7661-4ab6-a749-db8ee1bbfedd_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_f5486b89-7e5b-4ce3-86ca-5ed2428fe7db_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_c845c3fe-fe88-4144-a4b9-32a64185755c_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_8951fb70-7cba-4018-82e7-1614b7f868ea_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_a18ad819-8839-481e-bf16-34e61452c8ca_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_8ebc58a6-c371-4fde-9fdf-ccd753ebb038_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_61e3af6e-c651-46f1-bba0-69587c46d71d_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_8e645d65-655e-4049-9863-3486cc71f2a4_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_fcd7a4bd-2de2-427c-86e3-feaaf3e92152_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_74e0dd27-c413-4559-bec6-4edd3e852180_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_ded9aad1-2957-45b8-8280-334ca7b7bfbd_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_e7922f24-e280-4c03-ac38-4820482a19ae_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_01c27014-3fbf-40ba-ac7b-1687be170523_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_c57c2e52-3f2f-46ba-ac90-134a9f1c4d04_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_da484446-fdf8-45aa-a700-1368bb0f0eae_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_47cc1333-fbd3-4809-bf14-bd2760d8b452_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_860a7a48-fc0b-4c50-ba9e-dec82193755d_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_29b94bee-0c83-4933-bf87-13c47d26b631_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_4312a92d-c2cc-47b3-a4f9-aefb5a33ec11_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_317f760c-237d-4908-bd26-33ee3a0568d6_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_b7bc45b2-dfee-4117-af13-0df45727ef71_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_6c72765f-33f4-4013-9fd0-eb072f8d6cc4_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_0d4ca3dd-3a9a-4bf4-83cf-e1b9f4b32885_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>exel-20250513_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:afe5a4b8-9f29-4ee5-a450-454430305d0f,g:26d60216-afbf-47d0-b127-e6d76e60a090-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.exelixis.com/role/CoverPage" xlink:type="simple" xlink:href="exel-20250513.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_5a18cd7c-ad03-47a2-bc08-c2832d53b797" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_72fd3f4d-2abb-4c6c-90dc-9d936d7bb236" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5a18cd7c-ad03-47a2-bc08-c2832d53b797" xlink:to="loc_dei_AmendmentFlag_72fd3f4d-2abb-4c6c-90dc-9d936d7bb236" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_687a107d-7e5b-4e2a-b4ae-75f888cd94dc" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5a18cd7c-ad03-47a2-bc08-c2832d53b797" xlink:to="loc_dei_DocumentPeriodEndDate_687a107d-7e5b-4e2a-b4ae-75f888cd94dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_76260983-b72b-417a-b7c3-b0e54cad08c5" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5a18cd7c-ad03-47a2-bc08-c2832d53b797" xlink:to="loc_dei_EntityRegistrantName_76260983-b72b-417a-b7c3-b0e54cad08c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_bf5d507c-bcf9-47bc-ac74-8a015ead0c81" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5a18cd7c-ad03-47a2-bc08-c2832d53b797" xlink:to="loc_dei_EntityCentralIndexKey_bf5d507c-bcf9-47bc-ac74-8a015ead0c81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_bde84129-57c5-485a-8d9b-9c9c59e81b56" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5a18cd7c-ad03-47a2-bc08-c2832d53b797" xlink:to="loc_dei_EntityEmergingGrowthCompany_bde84129-57c5-485a-8d9b-9c9c59e81b56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_b718d15f-ad3e-40c2-90b1-53cf227f2ab5" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5a18cd7c-ad03-47a2-bc08-c2832d53b797" xlink:to="loc_dei_Security12bTitle_b718d15f-ad3e-40c2-90b1-53cf227f2ab5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_e6bed10b-625b-40f6-bd2f-aa74c503d963" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5a18cd7c-ad03-47a2-bc08-c2832d53b797" xlink:to="loc_dei_TradingSymbol_e6bed10b-625b-40f6-bd2f-aa74c503d963" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_2e24b0da-e96a-4601-9939-01628cf4a35f" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5a18cd7c-ad03-47a2-bc08-c2832d53b797" xlink:to="loc_dei_SecurityExchangeName_2e24b0da-e96a-4601-9939-01628cf4a35f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_deaf839f-5b25-491f-b811-44d8b1889064" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5a18cd7c-ad03-47a2-bc08-c2832d53b797" xlink:to="loc_dei_EntityFileNumber_deaf839f-5b25-491f-b811-44d8b1889064" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_15d229a4-0664-4353-adbf-86d1061ae784" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5a18cd7c-ad03-47a2-bc08-c2832d53b797" xlink:to="loc_dei_EntityIncorporationStateCountryCode_15d229a4-0664-4353-adbf-86d1061ae784" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_2300375c-dada-4e00-b104-46b298bfe1de" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5a18cd7c-ad03-47a2-bc08-c2832d53b797" xlink:to="loc_dei_EntityTaxIdentificationNumber_2300375c-dada-4e00-b104-46b298bfe1de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_b41ac0d2-05e9-4a37-8ebc-068b53cc2f96" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5a18cd7c-ad03-47a2-bc08-c2832d53b797" xlink:to="loc_dei_EntityAddressAddressLine1_b41ac0d2-05e9-4a37-8ebc-068b53cc2f96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_1eca2011-6d7b-4572-acba-39e53326f6b8" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5a18cd7c-ad03-47a2-bc08-c2832d53b797" xlink:to="loc_dei_EntityAddressCityOrTown_1eca2011-6d7b-4572-acba-39e53326f6b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_c1d83a04-6878-4270-bd22-34e9db2420ac" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5a18cd7c-ad03-47a2-bc08-c2832d53b797" xlink:to="loc_dei_EntityAddressStateOrProvince_c1d83a04-6878-4270-bd22-34e9db2420ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_eb27e9b3-fb32-4af9-bb31-c22d60f8afeb" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5a18cd7c-ad03-47a2-bc08-c2832d53b797" xlink:to="loc_dei_EntityAddressPostalZipCode_eb27e9b3-fb32-4af9-bb31-c22d60f8afeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_3c4c6036-200b-4f00-a90d-ebabc5573053" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5a18cd7c-ad03-47a2-bc08-c2832d53b797" xlink:to="loc_dei_CityAreaCode_3c4c6036-200b-4f00-a90d-ebabc5573053" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_ddbf1532-1ff6-441f-8ef9-b7618a1021a4" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5a18cd7c-ad03-47a2-bc08-c2832d53b797" xlink:to="loc_dei_LocalPhoneNumber_ddbf1532-1ff6-441f-8ef9-b7618a1021a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_912eeead-2526-4fad-ab48-a5d137506807" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5a18cd7c-ad03-47a2-bc08-c2832d53b797" xlink:to="loc_dei_WrittenCommunications_912eeead-2526-4fad-ab48-a5d137506807" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_e2171d4f-a9e9-45ce-9b38-652867489d55" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5a18cd7c-ad03-47a2-bc08-c2832d53b797" xlink:to="loc_dei_SolicitingMaterial_e2171d4f-a9e9-45ce-9b38-652867489d55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_f6a32444-0ddf-4414-aa30-8596a705d7e2" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5a18cd7c-ad03-47a2-bc08-c2832d53b797" xlink:to="loc_dei_PreCommencementTenderOffer_f6a32444-0ddf-4414-aa30-8596a705d7e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_61f484dc-0111-4ebe-9e9e-b48fe3fa69b8" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5a18cd7c-ad03-47a2-bc08-c2832d53b797" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_61f484dc-0111-4ebe-9e9e-b48fe3fa69b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_d68989ee-bc68-47b7-973a-1e478342a787" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5a18cd7c-ad03-47a2-bc08-c2832d53b797" xlink:to="loc_dei_DocumentType_d68989ee-bc68-47b7-973a-1e478342a787" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>exel-20250513_g1.jpg
<TEXT>
begin 644 exel-20250513_g1.jpg
M_]C_X0TO17AI9@  34T *@    @ # $   ,    !#.0   $!  ,    !"?8
M  $"  ,    #    G@$&  ,    !  (   $2  ,    !  $   $5  ,    !
M  ,   $:  4    !    I $;  4    !    K $H  ,    !  (   $Q  (
M   A    M $R  (    4    U8=I  0    !    [    20 "  (  @ "OR
M   G$  *_(   "<0061O8F4@4&AO=&]S:&]P(#(S+C0@*$UA8VEN=&]S:"D
M,C R,CHP-SHR-2 Q.#HQ,#HR-@      !)    <    $,#(S,: !  ,    !
M  $  * "  0    !   $L* #  0    !   !1P         & 0,  P    $
M!@   1H !0    $   %R 1L !0    $   %Z 2@  P    $  @   @$ !
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MDI__V?_M%2I0:&]T;W-H;W @,RXP #A"24T$!       *AP!6@ #&R5'' (
M  (  !P"!0 617AE;&EX:7-?3&]G;U]21T)?,C R,CA"24T$)0      $.Z*
M+VTF;HFD<OR1I?7(F<@X0DE-!#H      0L    0     0      "W!R:6YT
M3W5T<'5T    !0    !0<W138F]O; $     26YT965N=6T     26YT90
M  !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE
M5$585    !0 0P!A &X ;P!N "  :0!8 #8 .  P #  ( !S &4 <@!I &4
M<P      #W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %,
M90!T '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U
M:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $
M     !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#
M;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O
M;       3&)L<V)O;VP      $YG='9B;V]L      !%;6Q$8F]O;
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M=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP
M    #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N
M9P         -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P
M;&]N9P      .$))30/M       0 $@    !  $ 2     $  3A"24T$)@
M    #@             _@   .$))300-       $    'CA"24T$&0
M!    !XX0DE- _,       D           $ .$))32<0       *  $
M     3A"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H
M!@       0 R     0!:    !@       0 U     0 M    !@       3A"
M24T#^       <   _____________________________P/H     /______
M______________________\#Z     #_____________________________
M ^@     _____________________________P/H   X0DE-! @      !
M   !   "0    D      .$))301$       0     @   D    )      #A"
M24T$'@      !      X0DE-!!H      V$    &              %'   $
ML    !8 10!X &4 ; !I '@ :0!S %\ 3 !O &< ;P!? %( 1P!" %\ ,@ P
M #( ,@    $                          0             $L    4<
M                     0                         0     0
M &YU;&P    "    !F)O=6YD<T]B:F,    !        4F-T,0    0
M5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P   4<
M    4F=H=&QO;F<   2P    !G-L:6-E<U9L3',    !3V)J8P    $
M  5S;&EC90   !(    '<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG
M          9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N
M97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&4     26UG(     9B
M;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
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M=71S971L;VYG          MR:6=H=$]U='-E=&QO;F<      #A"24T$*
M    #     (_\        #A"24T$%       !     $X0DE-! P     "\$
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M!0$! 0$! 0         #  $"! 4&!P@)"@L!  $% 0$! 0$!          $
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M    % !! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <  @ #( ,  R #(
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M1T(                  /;6  $     TRU(4" @
M                                           18W!R=    5     S
M9&5S8P   80   !L=W1P=    ?     48FMP=    @0    4<EA96@   A@
M   49UA96@   BP    48EA96@   D     49&UN9    E0   !P9&UD9
M L0   "(=G5E9    TP   "&=FEE=P   ]0    D;'5M:0   _@    4;65A
M<P  ! P    D=&5C:   !#     ,<E120P  !#P   @,9U120P  !#P   @,
M8E120P  !#P   @,=&5X=     !#;W!Y<FEG:'0@*&,I(#$Y.3@@2&5W;&5T
M="U086-K87)D($-O;7!A;GD  &1E<V,         $G-21T(@245#-C$Y-C8M
M,BXQ               2<U)'0B!)14,V,3DV-BTR+C$
M                                                 %A96B
M  #S40 !     1;,6%E:(                     !865H@        ;Z(
M #CU   #D%A96B        !BF0  MX4  !C:6%E:(        "2@   /A
MML]D97-C         !9)14,@:'1T<#HO+W=W=RYI96,N8V@
M !9)14,@:'1T<#HO+W=W=RYI96,N8V@
M                                9&5S8P         N245#(#8Q.38V
M+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="
M   N245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S
M4D="                             &1E<V,         +%)E9F5R96YC
M92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$
M "Q2969E<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ
M                                  !V:65W       3I/X %%\N !#/
M%  #[<P !!,+  -<G@    %865H@      !,"58 4    %<?YVUE87,
M     0                        */     G-I9R      0U)4(&-U<G8
M       $      4 "@ / !0 &0 > ", *  M #( -P [ $  10!* $\ 5 !9
M %X 8P!H &T <@!W 'P @0"& (L D "5 )H GP"D *D K@"R +< O #! ,8
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M^!GXJ/DX^<?Z5_KG^W?\!_R8_2G]NOY+_MS_;?___^X (4%D;V)E &1
M 0, $ ," P8               #_VP"$  (" @(" @(" @(# @(" P0# @(#
M! 4$! 0$! 4&!04%!04%!@8'!P@'!P8)"0H*"0D,# P,# P,# P,# P,# P!
M P,#!00%"08&"0T*"0H-#PX.#@X/#PP,# P,#P\,# P,# P/# P,# P,# P,
M# P,# P,# P,# P,# P,# P,#/_" !$( 4<$L ,!$0 "$0$#$0'_Q $/  $
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M P$! A$#$0   +_
M
M
M                                         #%O'^1Z4Y4Y!QL
M
M#X8^^+]SBOS_ *<F?>X_N],@   !T#X_VZT.BO0-K_H?S3O]L0
M                                                      !COXOW
M:W^D.^\4\>Y)JF.?_9^*?_<72<FN=]>@  #A_P WZJI///I2:7:/4TH>?==
M
M    #C\=ZB_.'I[I?R_J@#7,6F^@/.6:.4<3  &B)K-Z)]!]2^=].U_T/YIU
MS
M       C-P3L&N'I'OGX  28YUP"R#N_H0  0:ZG[BA7U=VS:5W]YSS?ROB
M
M     $,^L.UX)]2]Q@ #,_)^*VH^@O-X $:N#<_K=Z/[\D)S/@]F?>WGP
M
M   1[X9SBLOHGT&0 !*OL+KBPWN?HP 8LX_R.JOS[Z1VF6EM_HWS)D/[7P@
M
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M@  11M6ORU(I6C&J/S/LNPPSG$ROK:>=;YUB0!C:8K0O3M4.()YUOG*)
M%'&F4);5      VAZ@L=^U I0TR@;:H L4K>XW/0  #045:Y0VFH M I>V&F
M@%0&F=;MJ      #T69;9UB0(CVK0IIEJ!E5/I,QV     J?OG5_>GP$MHM?
M7EJ!7]TYW=$GKGLSX 2'YIP>S'O7SZ /QK?\*7WNN( %?737=\3.N^R_I.GM
MKIV9W9_4X \]VN,;Y@"VBFEG-+@ =3*5=<H9374   #X3-K:X&FF5(D59WIW
MX_8Z@<2BTVF@    \UFV.,4      =@/3OCON@<.>>W7'!$P!I+K<])[5N
M*NKTJBOG] )91:^G+7]@#SZ:XQIF      /U/33COW, JWOG5->@&54^DS'8
M    "@77*+$U EM%KZ\M0.'_ #?JJ(\W^H.K?/\ H ?$V6=Y] 2-YMP,   "
M)O779E?'3?=_U'=?J?*MW](>7]YKD!M#RT;8?0"VBFEG-+@#B#S[ZXQ]F
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M"VBFEG-+@8<F/-]KCK +#ZWN0STU             \TVV.-T 6KTO:530
M    #IB/._KEC&8 _0_, &?HGT&Y;<L   >?+7&-<P!8M6]Q>>@      JUO
MG51>@&54^DS'8    "@/7*+4U EM%KZ\M0 !MJ:5+^=/3../B?= )GQV_P!+
M3 [*ZM$+>KNV8,]3]Q$#<WI;CZ.\Q]^^Q\0  ; \M6V&L MHII9S2X'#'E[V
MP_, ^&?XF>M;R[K;.$3K           /--MCC= $Q*VEY%@  !VR)GK6P
M$=)CS]:X\<  #M9Z'LMLL1(   \^6N,:Y@"3\6G#6P   W4+%ZW  JUOG51>
M@&54^DS'8    "@/7*+4U EM%KZ\M0  ,+<6Y;5CY_\ 1WQ '*_H_/;KZ/\
M,.*N/\DK-Z)]!:( 2][)ZPGWW!TH  !L#RU;8:P"VBFEG-+@"B33*'-J@ #0
M=R)/UM+F+37K;(<2         /--MCC=      S/$^CK+8    5Z7I3/?/4
M#47NYZS"K8   #SY:XQKF     !S!ZB<=P *M;YU47H!E5/I,QV     H#UR
MBU-0);1:^O+4   5X=+]Z16Z^[& &;N5<1Q3Q[DO#_F_2!S7ZORV_P#I/RYS
M_P"S\0  &P/+5MAK +:*:6<TN ,,3'GKUQZR    :R:-;6P4TS;$@
M#S3;8XW0     ,\Q/HHRV    'YGF^UQQ', "4T6O[RU    'GRUQC7,
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M2J:        8IF//!KCU, Y(V1^0!E)/H?RU[A$@  >?+7&-<P!8M6]Q>>@
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M->0?L_# P=Q/F%7'07HL@#G/U_DMV]'^8.S?O^> !L#RU;8:P"VBFEG-+@
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M*GO/'I;9Y: ;O3.VOT7YER%]KX8V!Y:ML-8-9Z$<MI&Q( ZV53Z9UUVIQP
M !^Y976]L^>FX        *6=,^F3     'TR?$VB4OD6)$/[5KFO0 97B;?\
M]-8   /Q*YKTBG-=C(:2U//21$2*CM,\+S      [Y"SRFF88D 07M2!UZ@
M  #L$+%:WE)6P%36F>"YC<0E)%K**7_4 K^Z<[MB1USV;N;UM'[^\YYHY1Q,
M     8FX[R:(?6W:'7_Q_M S5RGB4R^SNJ1M"B_7+4<O"?5;S(K8  #I$Q!>
MU8BS6/MHQZC9&HY\S=$RVK:P2M\PQ(
M                    Q[\;[E2'G+TYMZ7L)[EZ/EAV)UH
M    !MSB#]CF#Z
M      5H=%^@8[\*YS++L7K2P7N3I
M                                          86XORVJ_S]Z.S5RCB=
MH_?WG/<7H
M                    !IB:I?/7I/JWS_I6P>B/-/9?W?/
M                                                           $
M9^"=@UW]+]Z6I^@O-V5>0\;
M                                   &USTJ(\W^H9U=M=-27YUU^
M
M         !#?K+M7KWXOW3I[:Z<
M                                        &!.(<TSSR[AFJ8
M
M
M                                                       __]H
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MC3+QB;C/,:P5*@C&,8<90ED55\!0*%0D++*BX*3& ("&F?3 PMW8#!G,'Z>
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M5U0ZG%827+'Q%YH3\@^].,B"L'2HMR^(^)H'R%#/LW4&ZAG,._@0XUAQ -V
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M<(JG4>['Z"5F^@E9OH)6:4T%628K'L#=@;L#";?0 =F [ 8&WR]@83L(B/\
MN=?5RI<&=X=X81V:2)7&#)_HV_\ NR>%OW^,:1Y8]Z/[$IN6_A<$ ;-*TN&6
M'[MV5V7V(B.S32M"J1J.DOE2)34YRGP_L2GM;]RA(:&>1#R6T!VCPWL2>O2N
MB+:J=4C),ECX<Z]B=1%K_&ZD66.X^Q0),@WD6   ?\:__]H " $#  $% /\
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M/WPXCO@N*Q$J"?OSOWF@3,8=]4!V8H[X?_1^!W "A^AN=(>=4I=LHANPAME
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M[F:WJ:?+\:$_?'3O7_)W&QC\F\T9"0T?"55IY%4SG+):S4[XJE87*5H-!E
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MR401)^UI-@%YHV\,(+8HZJ"P:[SF3H+N\@19CQ 7DX "LT7=Y-U;->[7L?P
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M0?=IE7*%1ZK#FMQ7Y$T>1-$'0D$9C[5>0VHB2E;M^"+VF]0KUJDL!54  "P
M6 </RTLQER8C)GZ1XN:-1Q\O#Z#&E7#'ZP\B88SI, W:6Q6_:V<#?HC^X2AM
MI 3,UZ+]VPY0PTUW>3:;3<JWL<AZS5?1=WD""K?>QO9LSZA4+.%IBGQ7V4UF
MUNZ/7"D3YAJX*_,,?*Q\Z)O*5PJ8=93SE_+.!HLZ48HX!!R/V@<] JPBI$"#
M80;1QT:4*Y;;2'%3=K6P_??HK*E*6=C  7DT^&(&:T"[8GJCLK=B:]!F0^%+
MV4U"UN\:]4,/J7"D//9_MTTU,299[723O6CM:]$RE_JIM2SVKUU.*M<#0JP@
M141H?,SQX[BH?[:F[WVZ6 V<=#X$L^+/B-4OI'O<T=[T$!T,&4@@X$5@T6?8
MXV7&#CV-SAQB[1&_RAL3#!\GZVI_YHX\*_W#>5V0?#4](CID8#HXFNP5\+3)
MAY*J"2< *R:/O#5 U*.J@YH_/./H)!<^%,V7U7-K4UZHB^E1B-!Y$X11Q _F
M,P:QG1]VFVJ:CUEZ+#(C\J?%G"$B6=KMFY!^XW#,B@ $ *@!8 + ,AH+N$L[
M3P9\EZ*]X[1R Q]!?R4T^)*&SVI>&M/Y=6C*((28A +8RSSAF1:O&+Z+(D+R
M400 _$G$FTG'0?>)O,01.> &;& H^\33M.23[!J J&7H+D#=3"9RK;@.ERNS
MR8QRI5Y%7E'PT:+B^NI6U*:B,P?J!'R</IT?,9WV8-N;4N4O'OGU#/13=Y #
M\A@9NJ^6N=Y-Q@,:+-EGE(X!!Q!L_CGH%''*5@00;P:B*-)-:&M#BALXQ8<Q
MZ"DD=#G.<$%O&;!F:!5$% @!@!4!Q#0^#)/_ +$P5?\ C4],YGH?JN%(FLFA
M_MTTVQ:7KM9./G+G''1*H/&EQ9,^LG>%G: I V^@D3''BSH,<EZ"_N.L8:!G
MO6QJ1>LW^46L>*TT>?.;E.YB3]KA8!<.!9B&#*001<18:+O J:QQ@XMXFYPU
MY:(WV4(2YIV@.C,OXGMUQ^EU><H^>P7$94K:?/JKWCZ@=!]XGGDH@B?8!BQL
M H9\RH6*MR+<!^)-YKT!\0^#,@KY8/W3ZHZ+[O.$4<0.6##-36*/NTT;2&&L
M7$9$5CZE1\A#SI 5DT621XC;3^\>CW15KCPEF(  B2; !:3D*?#E$B1+.R.L
M;W.OHBX9DZ7R<T^+*&SVI?YI9[L,-'YN4/%DBOM2[^-+?=CAZ!CO<P1ER;,Y
MG1_3SCQ<-5#_ &_=FV ?$8=(CH#LJ>=BV0KTDWB4=I#'6+P<B*C1-YD\QQ'4
M;U.:FK1C+'@S(LF6*=W^4CT"+*EB+,0 ,2;*)NJ5\D;1ZSGG'[ZAD!P_*[N?
M'<5D?Z:G][78"NTCR)W*<82YIV8]&9=Q/S3GR=%MW:IK4/5<6<1YIR.5&ES!
M!E)!!N(M'E8?79O[A,%2Q67[W2;NBH9DX</+J,UHB6N)ZQ[*^LU8T:;-8L[&
M))M)/D8B@+GQI<%?/JOWA;V@=$?W&4,%F?@K\?-;.&/U%CYYCH2]VE<YS#5B
M3D!6:)N\H026 ![2<R8DZ^!MYGG96Z]FN5<SZA$FRC;Q.-9L%RK<HR'KMM/D
MUGBM#4XZR&WC%HS%%FRF#(PBI%X^UHN-6@TN8.4C AAB#;]L:/N[5K:IZR&P
M^PY@^6J\I7YIK^@5^;FWZ8-J9%4R3I-WC4,@<>!IDQ@JJ"238 +339B)*5(O
MXL>TWJ%7E82CRI9M1N:<Q>IS''&GC(\MLH./OB#ZJ<Y_T?QISG_1_&G.?]'\
M: 2V;XTNM"5A$'G*3&PVC C/T )NXJ4UL>J@YQ]@S(H$0050 !@!4!P'<MV;
MPD.TP_U&'[5NQ->'H3^-,$)L^!U)T1Q\X\7 =QW<^*P\1AT%/0':8<[!:K35
MZ$E5QX4O:?4+%[QJU1X-BN>XV!U1USD.B+SD#0NY)8F))M)-I]"4!148>*^T
M^LV+W1ZXT;>)UU2K>[7*/:;A1]XGF+,>("X#  5#T)_,S!&5)@?>?HCBYQU#
M&C3IS<E$$6/VM)N%YI\0[,M:D7JKGVFM8\5@'H366@BS$ #$FP43=EA%1%CB
MYYQU"P9"GRV[GP$-O^XW6]T=$<=]7H3;?Y@J393-S:W=!_4<J-_;]V:LU36'
M_&/W_IQ]"J;GNJK)15A%8\L]8\HDP+&))$#2)_PV?__:  @! 0$&/P#_ ,SL
M#7N62LNU<K-;+!1A6J9@NHN=XA8XP=1=B!S#$ZM*G--RR['ERU5=4T678.O:
M>:>"+N7FD)C10"^(7=QQP)Z/[!B2< -9.A@O&>+/23J<&@^%))(IZ"L98@^F
M-$@IN(%I$LAP59I3 #^.4(-$J[=6P5])+_AU5-(LL;>DZ$@_E['59@NS==,?
M>;1:T($M95,"4B3H&K%FV*N)T@@N%4\]US-4];>:Y,=RCH(=<G5@GN4BC[B,
M>N(YR=*"T6RG6EM]LIXZ:BID&"I%$H50/Q#^P7^;WV1IZFI)BL]F@(-363 8
M[J D *NUG.I1V\ 9ENESDM5D<^\9:MTCQ4RKS"9A@\[=);5T*-,(XU0="@#_
M (:8$ @\QT6XY4O558JH,&=:=_>9<->$L#8QR ^R72GRQFB&&RYP=2*-XR12
M7'=&+=3O$E) !B8R3CM4G8.P7+,%[JUH;5:8&J*VJ?8JKS ;26.  &LD@#26
M_7 -1VND5H,OVACJI*;'$L_,99, TA])1J T?.%TIS%?<XQI+3HXP>"VCNH$
MP(!!EQZQO37H_L%N%XN4XIK?:Z>2JK9VV)'$I=C^0:5^:+HSHDY,5GM['%:.
MB5B8H5&S$]\YYV)[7)BGIYI*>HIY%EIJF)BDD<B'>1T8:PRD8@Z0U=P9!F.R
M2? ,PHFH/*J@QU 7F$R8-AS'>'-RWEE=8XXU+22,0%50,223J  T-CL<[#)%
MCGQI67$"XU*8J:EA_IKK$0/M^<84-IJ(RUAM86X9DDYC3QL-R#'5KF?N?:[Q
MYM$CC18XXU"QQJ  JC4  -@ _L%2T02F.7-%R@HIE'JJ>(-42CTCU8!]/EU%
MD+'X+FBUS(T>/<]?1'KHVPZ=PN.76<,LK56$2'J\YW2)M9/_ +"-AL__ &D>
MT]=IJ!U:E51B3T  <YYAI3I<(!'F3,)6X9@)'=1NR^\T_I0H</;%CS_V#9!D
M /5I=*L.>;$TVK'\AY>3!#CBCUCRX?Z8HYM[_B.5_MC+E2#G2]PDK,N!_EU*
MV*FH;V;:Q$.GNCJ&LDLS%B6=V)9F9CB68G622<23MT2]7"#K,O9,>.KJ0PQ2
M>N/=4T)QU$)AUC#M+T_V#W&LI8NMJ\KU,-W15!+&&+%*@ #HB=F_%IB-8.P\
MJ]9JDB)I,MT!I()N;X57$8J/:Q(<?;#DR76=4K+S7%J?+MH+8&HJ,,<6PUB.
M,'><]&K:1I<+Y>JQKA=KK,U17UCZB[MS*-BJHP55&H  :4U%0T[5==731T]#
M2H,6EFE8(B##I8C2TY;AW9*R-347JK7_ #ZV;!IG]('N5]B!_8/-35$2S4]0
MC13PN,5='&#*1S@@X:2T<<,DF5KK(\V6+B02O5GNC2NVSK(=GLEP;IPY%OL5
MDHGN-WNLH@H*--K,=I8[%51K9CJ UZ6_+=/(M56 M4WJX*"/A%9+@97 .L*,
M JCF4#D7',M_JA2VZW1[SX:WD<ZDBB7U3NV"J.G2LS->W*-+C%:[:&WHZ*D!
M)2!.8GG=O5-KV8>A5<0[I3[UOR^[TF7E<=S)7,N$TPQVB%#N@^N8^M_ R+G>
MZ"W%>^%54Q0D?];#18SGO+W6."R)_-*3$@;2!UO-H!19JL]86."B"NIY,2.;
MN7.BO&P=&&*NIQ!':(["23@!K).GP.;.5CBJP=TTKW&F63'HW#)C_=HDL,BR
MQ2*&CE0AE93K!!&H@]DNF<\[7>*RV"TH#45+XL[NYW8X88UQ:221M2HH))TG
MI^%]EHLAV%'(I;A<X4N%UF0:MYT8_!X<1KW0)"/7:-(>+5PC+;4CHK:JCTA\
M$.&GG=N?R.V_--/.[<_D=M^::>=VY_([;\TT\[MS^1VWYIIYW;G\CMOS33SN
MW/Y';?FFGG=N?R.V_--/.[<_D=M^::>=VY_([;\TT\[MS^1VWYIIYW;G\CMO
MS32JD3B]=%>.%V1O@=LU$*2#_!Z97KZV8U%96VFBJ*NH8 &262!&=B%  Q))
MU#T$SWP1SO<[-<<IQ229DRA24]+4+<:#OGG@$\$K">GPW@H.#IO#O@N*R)Q?
MN3HX#(XI+;@0=8(_=-/.[<_D=M^::>=VY_([;\TT21>)1N(0ZX;A;+?,C G$
MAMR"-OR$:4=BXUV"GRZ*EEB3/5FZQZ!&. #5M+(7E@4G:Z,ZCG"C7I35U#4Q
M5M%61)/1UD#K)%+%(H9)(W4E65@000<".PWO.>;;BEJR_E^F:JN-8^L[HU*B
M+M9W8A44:V8@#;I>[WEO.=7DG+M;4$V+*M-3T,HHZ5.YB626:GD9Y6 WI#CA
MO$A0 !IYW;G\CMOS33SNW/Y';?FFGG=N?R.V_--(XHN+%WGFF=8J>GBH;<\D
MDDC!4C1!1XLS,0 !M.E-7<:<Y5F:<\YA9:ZLM\\=-'#:(F7WJBC^#0Q!W4'&
M5SCB^(7N5&/H73,N9KK3V2PV2G>JNMUJW"0PPH,2S$_D &LG4,2=*JW<&;#2
MY>L<;%:?-5]@-37U(!_Q(J(LL4"GF$F^W2J[-&E;BQ70EO\ +@H;:B#TE^"G
M3SNW/Y';?FFGG=N?R.V_--/.[<_D=M^::>=VY_([;\TT\[MS^1VWYIIYW;G\
MCMOS33SNW/Y';?FFGG=N?R.V_--/.[<_D=M^::>=VY_([;\TT\[MS^1VWYII
MYW;G\CMOS33A;F7,=P>[7Z^9;M];=[G*J(\]1+"K22,L:H@+$X]RH')N62^%
M5LI<ZYIMDCTUYS!5.PL]#.AW7A7JB'JI4.(8(RHIU%R<5#S'B1_*E8XK3VRV
M4$,:CF ZR&9C^-CIYW;G\CMOS33AA8+UQ1N-PLU[S1;*&[6]Z6WJD]//.J21
ML4I58!@<,00>WV2MNMUK8+=;+=!)4W"X5,BQ0P0Q*6>21V("JJ@DDG5I56;@
M?8J:>WPLT8SY?8Y"L^&H245 #&VYT/,PQ'^7SZ-4/Q3J:1F_R*.WVZ*(>DII
MG/\ ?IYW;G\CMOS33*V5<Y\1*[,&7:ZW7::KM4]/11I))3TQ>)BT-/&XW6UZ
MF]/T;K3Y,O+6/,\<?76>LW(W1I8SO"&1959=V0#=)YL<>;26"HS?/3U%/(T5
M33R4=('CDC8JZ,.IU%6!!T_K67Y)2>!T_K67Y)2>!T609Q,I7U$M%2,A],"(
M?\=(:/B%9(:FB8A7OMH5DECZ7DI69@XZ>K;'H4Z4=ZLEP@NEJN$8EHZZG8/&
MZGH(V$'40=8.HZ_1K,OYCM\=RM=:!UD#X@JZ][)&XP9'4ZU93B-)ZW)I.<;'
MB6CI<4CN<*\RLAW4FP]<A!/K='IKQ;JNT5$1PDAK8)*=@>CWQ5T$<&-1(=D<
M(,C'TE3$Z1-26"2Q6R3 M>KRK4L04\Z1$=;)^)</9#1Y*+&[9CK(PESS)4J!
M*Z[>JA08B*,'7NC6=K%CAR*FNK9XZ6CHXGFJJF5@J1QQ@L[LQU  #$G111,\
M&3[([K8*,XJ:ASW+5LJ^N<:D![U>VQ]"TY;LT?672]5"TU+B,53'6\K^QC0%
MSVAI9LL6A-VALU,D$;'OI&&MY7]D[$L>V>159PSW=UMEK@80TD"+UM565# E
M*:E@'=2R/@< -0&)8A02)HN'5IMW#VR*Y%-/61)<[I(FS&4O^[QD[=U4?#UY
MT9SQ;N*ESB52CMH4=H#X(<!IYW;G\CMOS33B95\0\UU.:JFRWFBI[5+4Q4T1
M@BEI.L=%%/%$""VO7CV"KM#7A\[9MI-Y)<LY>W*EX9!ZBIJ2RP0''40S[P];
MI-!DJU6?AW;F)$,O5_S6X;AU=U+.J0 ^E"?3T=\T\3<SWE7)/P9[E/! ,=H$
M%,T48':W<--ZJ3X6V..]4$RG'IQ?>TP^!08';[VOYM-]*2&-QL=$56_* #HL
MUBS1>K)*AWD>@N5738'THI5&B_ N*%?>H5P!I+_##<T(QQPWY4$HZ,1)I#2\
M3.'$%?#BJRWG+-08I NQG:BJR03SX+,-(J7)N<J9KXZ[SY7N(:AN:](%-/NF
M3##68RP[?)NV>\VSLEOMX6*CH8<#45U9+B(*2G4D!I)"-7,!BQP4$Z39VS[G
MI>"? >:5A:+=#,88JJ)20#&A>#X5@1@9ZAQ&3CU49 T6CJ>,C5EW;N)*L9CL
MR,\QY^H$)&./-I+Q X%<0JKB-PZMZBMON3:U6F_=5&\\CT2,T<L83;)2]7*H
M[K=90=(LU6!?Y?<Z)UI<T9;DD62:WU90.%WAAOQ2*=Z*0 !EZ&#*.Q560Z:K
M;_:G# )2Q42DA)KO/$LE542#G:)'6),=G=X=]V:M^+R>Y.F3?J.W>+1^C-Q2
MR50!.'F:ZPF_6ZG3!++=*AL=X*NI::J8DKAJ23N=0=>31\%<\W$KE"]3;F0;
MK4-W%LKI6Q_E[LQ[F"H8XQ<R2'=V.,.6\LKK''&I:21B JJ!B22=0 &@RGE2
MM8\+LGU3? 9$)"7BXQXHU<PYXHM:P [=<GJEP]'6< -I.EOX\YZH?W:$L_#"
MRU"=\>]-WD5OQK3@\V,G.AY%AX-6ZI:*QY>I8+[FF!<1\)KZDM\"CDYF2"-3
M(!ZYP?4CL_!C[HVOQ=>16C+U6:+-6>*I<OV2LC.$M,D\;R5=3'JU-' C!3M#
M,I&S18T&ZB#!1M_O.WT>#GWSL_C*=DL? ^S5;06QZ2*^YZ$;$&IWY&6AHY,,
M,4!C:9UV,>KQV<C)GU5?/$SR(N(MGI]VUWZ58,RQ(-4-<1A'48#8)@-UO9@'
MU7)CR]=:HIE'-4ZQ3*[>]T=>^"Q5 QU*LAP23_E8[.2$J((YT!QW)%#C\A!T
MWJ2@IJ5NF&)$.O;WH'*J.'N5ZS>R];Y=W,UPA;N:VIC/\,C#;%$P[OF9M6Q=
M?H5G$JZ0?O-U#T.6%<=Y2*V$]0,1MF==T$>I7V7)S#4&L:3*.2ZRIL>2[>">
MJ2.FD,535[NKWRHE0DL=>X$78.1Q?^O[=XB.5<LWYTO5/8<OVE-^KKISM8ZD
MCC08M)(YU*B@LQU :5V7\GS5?#[APY:(4-/)U=VN<1Q7>K:B,XQ(X/\ @Q-L
MU.[; $C0(@V*HP&O;V&.08K+"P>"925>-QL9&&!4CF(..E+:<V32\4,FQ8(:
M.XS87>EC'_MJ]\3+@-B3X] ==/\ <&0KVM>D)"76T3CJ;A02D8]754S'>0]!
MUJVU68>CPUX U,L@R5DZD2ZYIIHWP$IFB-75DD#4S4ZQ0+CLZQL-NF7*&BHX
M*:AMN:K;%0T*1JL,4<%'5K&BH!@%4   #4-,NW"JLUZANEZM-'6U-RANLXD2
M:HITD=D1]Z(#>8D*4*]K#3CEP!DOTV8\G9"GDER_53,62"2"M>ED$(Q*QK,I
M5F1>Y#JQ4#$Z6JRY?0T7#[CU2,JV>,#J8:BI:5@B*!@HAK(R4Z$F*C5V/B_4
M2ZY),YWH,=9[RLD0;>TH[-EK(]HA-1<<VW.FM<$8V!9W F=CS+'%O.QY@#I1
MV^F!6GH8(Z> '60D2A%Q_$/1NN6\Q6V&[V*]TLE'=;94+O1S02KNNC#;L.HC
M6#K&O2?+E5UU=E.[F2KR)F*37\*I%/=4\K[/A%-B%<>J&Z^QM7HLCC%6&!P.
M!],$:P1S'1>&F>+F)>(^5*4&WU\[827JV18*L^/JIX!@LPVMJDYVPY5;P*R#
M=-VOJXPO$R]4KX&GIY!B+7'(NR292#-AWL9W-KG *H"JHP51J  V #D&ZY@I
M73A=E"H1LRSG%1<ZH /';(F&!*D8-.1WJ8)J+ZH*6E@CIJ6FC6*FIHE"1QQH
M JHBJ %"@8 #9R.*AD<N4JK=&A;7@BVRDP4=H8GLU+:[53O5W6ZSQ45KI(QO
M/+4U#B*%% VEG8#3)>34*G_:]DH;8[)WK/30)&[#M%@3R."J!B$:Y7MF3F)6
MFIL"1VL3R.#GWSL_C*=DXB[[%MRFLRICS*+=#@!^7D9,^JKYXF>1<\OWFG%5
M:[O3O35D)VE7&U3KP93@0>8C'2[Y4NP+5%LE_=JK#!:FE?$P3K[==O0P(YN0
MR,,588,.T=/Y%>*KK<T932.GJW<C?JJ/#=IZGI)P&XY]<,?5=BFR%E:LW,S7
M.$?SNX1-W5NI)!WJD;)I1WOK5[K:5T"J,%48 >A9LJ4N^D5;)UMVJTVT]#%@
M9Y,>G#N5]D1I16NW4Z4E!;H(Z:BID&"QQ1*%11Z0'(K9HSA)#!(Z'MJI(TED
M<[SR2R.['G9G))_&3R.+_P!?V[Q$<FZYCS!<(;58['2RUMUN4[;L<,$*EW=C
MV@-@UG8->C7*9I[=D2R2NN2,K.=T1QZU^&U*#4:F9=9QQZM>X7U1/9*'-N2;
M[4Y;S';C^[W&F(P=,<6AGB;%)HF]5&X(/:.O2XU]QR_-8LS95FAH,RM$CFV5
M$\D>^)**9L<05&+QL=Z/$ E@0QTSK37(B*7,66G%G+?YA>WT,RX$^QII!^(Z
M65I5WXUS?0&1.E12UF(TL^>*KC3+=<BS4EO@2GL16&LM]+5PK\%,TC4<;(@+
M+$71\02#CSZ4&<<EWJ;-MSXCPQ7',F:ZM=R=YH]X&CZHEC$*>1I%922S/O,S
M$D8?]IV7:!MZZT5PBKJK<P)C@:OBD!;;AW-+(=?-V/BY]]+[X_-R!UTR1;W>
M[[!<<.C'3^+A_:+^?3^+A_:+^?3^+A_:+^?3^+A_:+^?3^+A_:+^?3^+A_:+
M^?3^+A_:+^?3^+A_:+^?2&RY*R[<<V76H;=CH[7 U1ATF21?>XU'.SLH'3I+
MQ X@O2UW$FXTQIK?;Z9A-362EE ZV..7#"2>79)(O<@=PF(WF;D73).8!\&F
MD_><OWR-0T]NN$8/4U,>.T G!UV.A93MQTO>2,X4'\NS%EZ?J:Z$8F.16&]%
M40,>^BF3!T;H.!U@\BSYHRW<9+1F'+U6E;9KG%WT4T?2-C(P)5U.IE)!VZ4^
M9*)8[?F2ULE%G3+BMBU#7;N)*X]T89AW<3':NKOE;#D);+%-#4\3,W0RQ96H
M7P<4<([B6Y3IZR(G! >_DP76 V%365E3+75U;-)4U]=4.9)IYYF+RRRN=;,[
M$DGIY%LR'E93#+4CX3?+VR;\-LMZ,%EJI1L)U[L:D]VY V8X6+(V4:$4-CL-
M.(:=2=Z65SW4L\S[7DE<EW;G)Y/%;X[0?9E)R 994B#'!2[!<3^/3^+A_:+^
M?3^+A_:+^?3^+A_:+^?3^+A_:+^?3^+A_:+^?3^+A_:+^?3^+A_:+^?3^+A_
M:+^?2"T98M-;F6[53!*>V6JGDK)W8[!N0JQ'IG :4'%;BW3PQYIHE+Y0R8K+
M.ML>12IJZMUQ1ZG=)"*A*QXD[Q?O>1P4^L;YXO3<C@Y]\[/XRG9.(WZBS?9T
M/(R9]57SQ,\D9FL]-UN9\I1O*D:#NZJ@[Z>#MLN'6)VP1ZK174AE8 JPYP=G
M(M.:[9O226]RM=1 X"JI),!/ ?;+K7H8 Z6R_6>I6KMEVITJJ*=?5)(,1CT$
M;".8ZNP?NS1U6;+RCQY>MK:PI&IZJ8<T<6/_ #-@HY\*NX7"JEKKA<)GJ:^N
MF.])--(<7=CTD_F] LQP51BQ.P :/FNZ4_5W_.*1S(CC!Z>WKKIXM8Q!?'K&
M],#FY-R^*S>X.A]N_NCR.+_U_;O$1R;-P,L=64@,<-\S\8V(WU+$T%$^&&HE
M3.XV'"/DQ6BQ6NMOMVGPZJUVVGEJZAL=AZJ%7;#MX8:"6EX47&AC;6#=*FCH
M&P[:3SJX_)HTAX;QRA=J17>VLY](&H'_ !TDDNG"#,P@A&])4T=**Y !VZ1Y
MC_=HU#<Z:>UURG!J*MB>FF!_5RJK?W<FR9 RC$#=+RY:IKY%+04%'&1\(K9\
M/41 ZAZIBJ#6=+%D/*E+U%JLL.Z\[ ==55#]U/53L.^DE<EF/XAJ 'H9%_[H
M>'40DOW#"2%,STZH3C10RM)#52!1BT:=9)%-T1R;VQ3I9&X'T4-[S-2Y@HJK
M,V4:BMIZ6KM;I2U*2QSF=T4@-(-QAJD7NEY\+=D'.%NBJZ.LRW3V7,5L8K(C
M#X*L$R!AB#@0<&'/K&G%*W<5S O *&IFK\H9P-=3/4RUP(6&&GMXEZ]I:Z+#
M>0+JEC+=ZQ;3-_\ W8YSMSVZPP==:N&]NE(*XA#3^]ZL'2E@WD+C4TTDA&.[
MV/BY]]+[X_-R.,AO=DH+R:6X644QKJ:*HZL-3U)8)UJMNXD:\-/Z)L/DVE\'
MI_1-A\FTO@]/Z)L/DVE\'I_1-A\FTO@]/Z)L/DVE\'I_1-A\FTO@]/Z)L/DV
ME\'I_1-A\FTO@]/@MJMU+;*8''X/20I#'C[6,*.6F9LK4Z1\3\G4\C65M2BZ
M4>)>6VRMTL<6A8][)[%VTDBFBDIYX'>*HIY5*2121L5>-T.M65@00=AY%NSQ
M85>LI,!29JR^'W4N=N9MYX<3J$B'NXF/>MJ[UFTL>=,IW!+GE_,%,M5;ZI=1
MP.IHY%VJZ,"KJ=:L"#Z-WSWFB0O3T($-LM<3 5%PK9<1!20 ^JD(UG8J@L=2
MG2^9\S?4BHOM^EWGBC)ZFEITQ$%)3@ZQ%"NH<Y.+'NF/(M5@L-OENU]OE5'0
MV>UP#&2HJ)C@B+T=))U* 2=0TCM1:*XYTO\ U=9G>_H/\:J"X+3PDZQ!3@E(
MQSZW.MCRN*WQV@^S*3D<1Z>]6FCN\$.6Z1X8:V".H1&-80659%8 D<XT_HFP
M^3:7P>G]$V'R;2^#T_HFP^3:7P>G]$V'R;2^#T_HFP^3:7P>G]$V'R;2^#T_
MHFP^3:7P>G]$V'R;2^#T>*S6BBM,4AQDCHJ>.!6/21&J@\K@I]8WSQ>FY'!S
M[YV?QE.R<1OU%F^SH>1DSZJOGB9Y1N%KI^JROFQY*FV*H[BFJN^J*;H Q/6(
M.@D>IY+\-KQ486Z[O)4Y6ED.J*K[Z:FQ/-* 70>N##U7+KLRWMR8J<".BH4(
M$M54OCU<$0/JF//S#$G4-+CFB_S"2X7!L%A0GJJ:!<>KIX0=B(#^,XL=9]&A
MMU3$6R_9]VXYD?U+0HWO=/CJUS.,"/6AM%1%"(@"H@&  &P #DW+XK-[@Z'V
M[^Z/(XO_ %_;O$1R))YG$4,*%Y9&. 55&))/0!IGG/=6<7S1>JJKIEQ)"4JO
MU5+&">98$0<B:S"JGLV3LO)'4YSS# H,L:2D]324Q8%1//NM@2"$4%\#W(,.
M7L@Y9H\O4"*.ODA3&HJ7&V2IJ&QDF<\[.Q/XN0]NS?E>U9GHI%*&FN=)#5*
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M%;*2NJ9*(PPO*&(>0),S8#=YACV*2T%HK=G*Q=969(S Z_P]45P:"8C68)P
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M@RL#@58'80=1'(M69[))U=SL\XF@4DA94V20OAZB5"5/IX\VEHS19I-^BNT
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M0\C)GU5?/$SR:^[W.H6DM]LIY*JMJ7. 2*)2S,?Q#2\9LKPT?\QDW;=2-_\
MQZ./N8(O3"ZVZ6)]%<WYCI=[)]FGPH:20=S<JN(XX$'488B.ZYF;N=@;3 #
M#8.P)GNRTIDOF5XB+K%$I+U-MUL^H;6@.+CV.\.C0%3B",01SCD6[,U-ORT(
M_=;_ $*G^(H9".L&'.T9&^G;&'/I1W.W5*5E!<(4J**JC.*212*&1E/00<>1
M<OBLWN#H?;O[H\CB_P#7]N\1'(CX(T-/5V?+&7(Z:ZW]YXWA-XJIEWZ<Q[P'
M64U/TC4TN/\ ICE*TD:NR:T8@$J>D'FT$>5^)>:+%$-D%-=*DQ#M=5([I_\
M;H$BXN72I"@C>JZ:AG;7TEZ?0QS<7+K3*1@6HZ>AIV_ZDIP=!)G3.=\S81LC
MNM?/4Q#THG<QC\2Z    #  ; !R'D<[J("SMT ;=(KK?:1J7.7$5XKU?:>0
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D%$%P$,8@B50ZQ* JAR1@-8.BHBA$0!411@ !J  &P#_RV?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>imagea.jpg
<TEXT>
begin 644 imagea.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !+ 1,# 2(  A$! Q$!_\0
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M2W1^V&G2M<6%O*^-\D:NV.F2 3BK-5-)_P"059?]<4_]!%6Z19Y+^TO\;'^
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MM B>ZM-3FX"\<PMW*OP,>N"*_+M3E58C!Q^7>OI3]LC]I(_%KQ*_A?0+D_\
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M'PSX=T[0VN,"5K*V5&<#H"1R1[4M!ZG2W'_'K+_N'^5?B9=?\A*X_P"OEO\
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M6Y^-WQF_Y*WXY_[#=[_Z.:OU2_9]_P"2%^ _^P+:_P#HI:_*WXS?\E;\<_\
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MHR<[(4"#/K@5\SDN35<IJ3M5YH2Z6/J,\SZGG4*;E1Y:D=+WW78_'GXP?O\
MXP^-H8@TT[Z[>(D48W,S&9@% '))/%?J]\%M&O/#WPA\&Z9J$+6U]:Z3;0S0
MM]Y'$:@J?<&M]/"VDQ7GVN/2K%+O=O\ M"VR"3=G);=C.3SS6J.!7UY\>HV=
MS\NOVG/V=_B+X4\;:UXEUB&Y\6Z;?3M/_;EK"7VJ3D+)&.8MHP /N\9!KB_!
M?[2GQ*\!6B6FB^,KV.RC&%M+HI<(@]%$@.!["OUX9=WTKD]:^$?@GQ%(9-4\
M(Z)?R'GS)K"(L?QVYIW%R^9^5'Q ^.WCOXM+%9>)?$=SJUNKAH["-%CB+]CY
M: ;C]<U]-?L2?LRZWIOB6#XA>+-.ETN&UC8:38W*%9I'<$&9T(RJA6(4'DDY
MP,"OL/P_\,/"/A619-'\,:/I<JG(DM;&-''_  (#-=.HQ2N'+K<6BBBD6%%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7!_%*RUK7
M=(CT'10\3:HYANKX?=M;?'SM_O$?*![FN\J/UK&M3]K!P?70TIU'1FJBW6ID
M>$?"^G^$?#]GI.G0B"TMDVJHZD]V)[DGDFME5"]*%IU53A&G%0@K):"G.523
IG-W;U"DVBEHK0@3:*-HI:*5@"BBBF 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover Page<br></strong></div></th>
<th class="th"><div>May 13, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">May 13,  2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">EXELIXIS, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000939767<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock $0.001 Par Value per Share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">EXEL<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-30235<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">04-3257395<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1851 Harbor Bay Parkway<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Alameda<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94502<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">837-7000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( #V!K5I&QTU(E0   ,T    0    9&]C4')O<',O87!P+GAM
M;$W/30O", P&X+]2=K>9BAZD#D0]BIZ\SRYUA;8I;83Z[^T$/VYY><@;HBZ)
M(B:VF$7Q+N1M,S+'#4#6(_H^R\JABJ'D>ZXQW8&,L1H/I!\> \.B;=> A3$,
M.,SBM[#IU"Y&9W7/ED)WLCI1)L/B6#0ZL2<?J]P<"A#G>B4^BQ-+.9<K!?^+
M4\L54Y[FRF_\9 6_![H74$L#!!0    ( #V!K5I/^XLK[@   "L"   1
M9&]C4')O<',O8V]R92YX;6S-DL%*Q# 0AE]%<F\G;:FPH=N+XDE!<$'Q%I+9
MW6#3A&2DW;<WC;M=1!_ 8V;^?/,-3*>\4"[@<W > QF,-[,=QBB4W[(CD1<
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MM5II ,,X?<D3$L/<@HL(2W@4R]9<X%L:+R/6ZK3;W5:$:6RA&$=D8'U>+&A
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M"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @ /8&M6AE%%?4W 0  )P(   \
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M>1<W]T6NS>,)KM\,<'AT_@%02P,$%     @ /8&M6F60>9(9 0  SP,  !,
M  !;0V]N=&5N=%]4>7!E<UTN>&ULK9--3L,P$(6O$F5;)2XL6*"F&V +77 !
M8T\:J_Z39UK2VS-.VDJ@$A6%3:QXWKS/GI>LWH\1L.B=]=B4'5%\% )5!TYB
M'2)XKK0A.4G\FK8B2K636Q#WR^6#4,$3>*HH>Y3KU3.T<F^I>.EY&TWP39G
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M+GAM;%!+ 0(4 Q0    ( #V!K5I/^XLK[@   "L"   1              "
M <,   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( #V!K5J97)PC$ 8
M )PG   3              "  > !  !X;"]T:&5M92]T:&5M93$N>&UL4$L!
M A0#%     @ /8&M6J(E\9%.!   >Q   !@              ("!(0@  'AL
M+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( #V!K5J?H!OPL0(
M .(,   -              "  :4,  !X;"]S='EL97,N>&UL4$L! A0#%
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K  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     )  D /@(  /T3      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="exel-20250513.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="exel-20250513.htm">exel-20250513.htm</File>
    <File>exel-20250513.xsd</File>
    <File>exel-20250513_lab.xml</File>
    <File>exel-20250513_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>exel-20250513_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>17
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "exel-20250513.htm": {
   "nsprefix": "exel",
   "nsuri": "http://www.exelixis.com/20250513",
   "dts": {
    "inline": {
     "local": [
      "exel-20250513.htm"
     ]
    },
    "schema": {
     "local": [
      "exel-20250513.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "exel-20250513_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "exel-20250513_pre.xml"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 3,
    "http://xbrl.sec.gov/dei/2024": 3
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 23,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 23
   },
   "report": {
    "R1": {
     "role": "http://www.exelixis.com/role/CoverPage",
     "longName": "0000001 - Document - Cover Page",
     "shortName": "Cover Page",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exel-20250513.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exel-20250513.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover [Abstract]",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Issuer Tender Offer",
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Tender Offer",
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Soliciting Material",
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Written Communications",
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>18
<FILENAME>0000939767-25-000074-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000939767-25-000074-xbrl.zip
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M$$S';3\,EIQ,T\K5*X6R!G2O]'^\'#5+DOSZ<\4RR^>21,QG0YP?"=0$SR#
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M!S]2<<\B\N%#XQG'QS?Z&OMUN%J!BXXH(]T)<53Z%?R2>U!+3&US+^5&N21
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M%74MOJ) =[]O]Q+\L*W2.*K-BFQI,@U[+V9E_4VI?<ZV$0()Y!9]^A;B#Z*
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M*U5Z>#C).!\XD[S=^K;GX,\-A[28!*"@H6]$0D)<T![D@-@",'9^70["TA\
M.*"D (MV ,H#'8#&.1IBW#".9KH:CH1="9&+G\A%/Q4E[BG@%9F)7;^:M?@\
MZ3FQ38FX0J8BM.]L$L!]@S<6W-D8^^*]??%@E;#C $QP>'-G#,:#2*'OA4>A
MO'P]=V'"7=,#2ZC3$7G-T0$$"@TTGL#S4R8*>PSAB;+0MK$@[L T 03@!6#
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M)^:(_^PJ\;_VHOA?IN1=%#C/$\EWUQBJ/'^7O\O?Y>_R=_F[_%W^_RL_3RG
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M*>%R6:+HE#3J-:8Q9=%*IQW="7'W::Q3M 2_JSM83AP+-(YZOQ/Q<Z+!E:>
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M#R>O()^,=-_-AZN2C A)4U,<\ EQ?"[3P/R+\7SM3- ISWN0:@A[KKR)5]K
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MZ=17WE?FKGT-M;(::)O;*6U;H$AZH9"44X(G*VXSVCA\IB0FG8-/D6NONA;
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MI.SG/G85$^43)1/'L*NJ(JE1 !-2:67_%8%BPX+%0MKT\M^4.7**]&7;)6S
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M+>X"Y=[X$E??6^AY_C)[Z>UC9*20D7SXI)]F<_L4.2UAVB!CR<$KTK-AM5E
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M&*IM#>)Q_U)EE87XLS*<?UA%-95 ,;E\"^Y?@9P[#IBVGU-) ( 95\Q!<PH
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MX52%.F<2ZX[-ZZ7P$-A\K.*,.*;Y/>7^KHM;Q4,'=RCN/<_(*AM9- ,,EA#
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M'!]HMOD^<[%WP(!W ,2 SMELWGQD3A7%YLZ1)80/&+7560<ZJ\^PA]%DDD'
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M7M3UG>:\H_VZ-Y32@70U6R!,W(AB>/WC9?=ZDW"RLHX6SQ/+XUTO$,C,L(+
M*6CZ;$01@"0U)_:1'T]P]*(%@2TJ*UQ@0GV\IWVX!+Y;?X/XZT+:V=Q=NLS2
MUP7E71;5$9WQUV%VV!E+*_,)[!!P8:,*!7K]98E1]<$WTS,9HK5]-0ND!P\=
MLQHXM'FAZ.4E=55F2IH*0\+%!D%X  =4I#$F!E5TN'JV!ZIMU+Z*@A:&[D42
MU:09TW.7Z3E8U5? :R[GZLVU3U,JQZUCN@<\DO;],\)WS0S0;O3DK2L:MBPK
MSI47A^30@VBL>$?$,*]$WS/4Z@L$U<RNA$^OM21[44[P^#B7[B1X1V4E3<#
M$XJR7:+JE,R:5JKEA[L?4H@P:;PL[[2Y>2A/5P $4SXOS/U@O^)BVU(;^P+G
MD_)3B&4=!G,*T]"]U7'!NT(0>W6O6U&VG"C'P$=6$!8.WJ&[]G#!CX8T=GA$
M5,UA',!+OTP_Y]T@'>Y%%'2@(1=X6Y0J'OV3D5ICJU 7JJ1W 'GJ_0@!UX$P
M]?&@5 E[E^S.(-;/W4J&(_I%W!+$^EP@: SF9KL1F:QTK'T\LS:N<R;U@A1H
M;S,/R_Y<)LN\;$+/YYO=XC/5V*!SOF-<7!@.K:2GQ4B&(.U& 9?TE<,%*IH
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M'OMFA<7)2"Q")E:Y[BR0J[71L7PU W[9:[)=AKQ\]Q7_5,/)>I(E9"=<":6
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M+2JT.\W6<VF!Y0:J24CB C"VY!F0,^).=C>MANMX(OV6EKH2:^^*<'8GDS\
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MSG2NJUOA^68(,$1B$H9'7LJEC.] Q>J1=G&7R:<%PDO1>]%.SIP..48QR7\
MI2>QU#?QOQ><E"L%Y<0W%M?$-]B+,L@)M+&!=.^C6-U8%\3PC)IO"QK6&&[O
ML\5J8,I:-JS(-0N"<(<A$OC44$+0BH3QT?E^3#U?N,ACOVFNONB7_\2_X#?E
M\V>6"KX2G)#-&JZ>\XC%L<=/*T:QI3AT*2#91>GG04YMU'.I170)E7PUO)"A
MS-NC>I\*X2E*5IZ&FU+V3AOF*4PTBU)#Q02*T-$AB=#@1Y ;S1_X=:^(V#:N
MTY16M6]:XU(H"B.D)TF8U-$&N?HT,0@0B4Y,,7"*-LA$)7XDH*C-Y?P $H)'
M5<R@ I_Y82>)OX] Y",,0.X0&3J[<V"QR!F3U*!?I_WX@?Y^;,07XK,>E=K7
MRTOUH:GMX$IGKXG87-F9._/!.'X$U>)_()2&;JV^J()RD8Z9/6XSAZEFAKF!
M]7J\=!+/;9N6_>)ATHD5T%LGE.4.8]B1F\C1#8M_.W@TJ"S-H[2R-)&J!!1S
MT:4\+$)><4C;AUY*N"XN>=ER3=W(@+_-VU&B% VZH2B&-U! L9=SV[W4(NQ9
MLPN%T%52<5,X%0R^+=\LLH7A7(VR6U.[][H^?:.EGYZJA(H"[=FI61_V73'L
M(?<OF(O&7&$E<?I!" #%6;Z O:2L)H3*I >KS9SJ3H:NMOM[O"A-T"^?D?Q4
MY\>JK>UCO\[GXM'=/X"5^TMT@C@:?>,EAEY:<&E _!TL12"G#QE[$&D#]1+\
M+L 9_PI&FNZ&RJQCQAG8Y\!3FJ(T6'+^71D]X#ROS_I@(JW=.G*+@TD"6BI>
M_DK654T- 010@_[KA[L7U/\:,'@5(*.XHJPRSK]2 $H2>5!55?7?(EOA",\_
M\T?H6D_I!J,TBY%-I:W>>5)+%PZ2]COW,IJJLE[12L!X7YA*%9I[$'OK3V)!
M7:FJTMCD, ]0^@H_>M#P$GG+&IFB+,7#*!=G 5QE<";1WK)I5Z<J#B_8:F/K
MHA7??63;<J G*'/$8_(ZAB-D9;1D=\N]$#6A8<J<QWB%-R@].I?O6\PQ^$Z
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M[IPLFM5O@=@DQX_KC2D&LOQ;C:6JSY]$B-C'3J=M)6*RYHI#L-2].$$>>T<
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M'%PL>&GR8@GA:?UK9_G-0Y%>79< !SC<#MO^M'C#C0XY%0PF!B>0:AU"3L,
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M=XK/QM@VBFDA0\8C*$F,(#5*P\0H Z54<4BT$ %A0S$[)'9DY*P\E U]L$X
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M=EQ5\1AMF PF/*1\,74[2_F;Q3?<G>&!H[W['[J7;FO\T=[_ 5!+ P04
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MN5^]G=JICL;ZGN?'GBU"N$F#,&+_C'D VU&*?GJY7HLP=J.0<<]A5X%_+\%
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M(+-]H)FBI"3'$:C!%*_D;-7L=+0NJ>T$I0+@O[YOUW+EP1E_3V+]FGGPM.A
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M,#(U,#4Q,RYH=&U02P$"% ,4    "  ]@:U:XW\&8V0"   &!P  $0
M        @ %@$   97AE;"TR,#(U,#4Q,RYX<V102P$"% ,4    "  ]@:U:
MU=T09:JG  "'V   %               @ 'S$@  97AE;"TR,#(U,#4Q,U]G
M,2YJ<&=02P$"% ,4    "  ]@:U:>00^9RP*  !]50  %0
M@ '/N@  97AE;"TR,#(U,#4Q,U]L86(N>&UL4$L! A0#%     @ /8&M6KX1
MYXZL!@  ZC   !4              ( !+L4  &5X96PM,C R-3 U,3-?<')E
M+GAM;%!+ 0(4 Q0    ( #V!K5H*?9+IU#   *[/ 0 :              "
M 0W,  !E>&5L,C R-3 S,S%E>&AI8FET.3DQ+FAT;5!+!08     !@ & (X!
(   9_0     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>exel-20250513_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="exel-20250513.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <startDate>2025-05-13</startDate>
            <endDate>2025-05-13</endDate>
        </period>
    </context>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-21">2025-05-13</dei:DocumentPeriodEndDate>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-22">0000939767</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c-1" id="f-23">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="c-1" id="f-1">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-2">2025-05-13</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="c-1" id="f-3">EXELIXIS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-4">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">000-30235</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-6">04-3257395</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-7">1851 Harbor Bay Parkway</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-8">Alameda</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-9">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-10">94502</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-11">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-12">837-7000</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="c-1" id="f-13">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="c-1" id="f-14">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="c-1" id="f-15">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="c-1" id="f-16">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="c-1" id="f-17">Common Stock $0.001 Par Value per Share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-18">EXEL</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-19">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-20">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
